Drugs / cysteamine-pantetheine disulfide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06990984 | Oct 2025 → Sep 2026 overdue | Leigh syndrome | Thiogenesis Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-05-18 | Thiogenesis Therapeutics, Inc. | Thiogenesis Announces Positive Results from Phase 1 Dose-Escalation Study of its Lead Compound TTI-0102 thiogenesis.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cysteamine-pantetheine disulfide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06990984 ↗ |
| Known as | TTI-0102 | “TTI-0102: cysteamine-pantetheine disulfide, powder for dissolution in water for oral administration” NCT06990984 ↗ |
| Route | Oral | “powder for dissolution in water for oral administration” NCT06990984 ↗ |